On ECHEMI
Home > Drugs > Chengdu Brilliant Pharmaceutical Co., Ltd.
Chengdu Brilliant Pharmaceutical Co., Ltd.
  • Founded in:

    1995-10-10
  • Country:

    China China
  • Address:

    No. 263, Hexiang 3rd Street, Chengdu Hi-tech Zone
  • Tax NO.:

    91510100633104205M
  • Registered Funds:

    450 million yuan
  • Website:

  • Email:

Related Drugs
Sodium Glutamate Injection
The main ingredient of this product is sodium glutamate. Its chemical name is sodium L-2-aminoglutarate.
Name Description Content CAS NO. Registered Holders
L-(+)Sodium glutamate

In severe hepatitis or liver dysfunction, the liver's conversion of ammonia to urea is impaired, resulting in increased blood ammonia and encephalopathy symptoms. The intake of glutamate and arginine is beneficial to reduce and eliminate blood ammonia, thereby improving encephalopathy symptoms.

More

In severe hepatitis or liver dysfunction, the liver's conversion of ammonia to urea is impaired, resulting in increased blood ammonia and encephalopathy symptoms. The intake of glutamate and arginine is beneficial to reduce and eliminate blood ammonia, thereby improving encephalopathy symptoms.

142-47-2 4
Cefuroxime Axetil Tablets
The main ingredient of this product is cefuroxime axetil.
Name Description Content CAS NO. Registered Holders
Cefuroxime 1-acetoxyethyl ester

Second-generation cephalosporin antibiotics, which are hydrolyzed into cefuroxime after oral administration to exert antibacterial effects. The activity against Gram-positive cocci is similar to or slightly worse than that of first-generation cephalosporins, but it is stable against β-lactamase produced by staphylococci and Gram-negative bacilli. Sensitive bacteria include Staphylococcus aureus (sensitive and resistant to penicillin), Haemophilus influenzae, Escherichia coli, Proteus mirabilis, etc. The mechanism of action is to inhibit bacterial cell wall synthesis.

More

Second-generation cephalosporin antibiotics, which are hydrolyzed into cefuroxime after oral administration to exert antibacterial effects. The activity against Gram-positive cocci is similar to or slightly worse than that of first-generation cephalosporins, but it is stable against β-lactamase produced by staphylococci and Gram-negative bacilli. Sensitive bacteria include Staphylococcus aureus (sensitive and resistant to penicillin), Haemophilus influenzae, Escherichia coli, Proteus mirabilis, etc. The mechanism of action is to inhibit bacterial cell wall synthesis.

64544-07-6 17
Cefaclor Dispersible Tablets
The main ingredient is cefaclor: (6R,7R)-7-[(R)-2-amino-2-phenylacetylamino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
Name Description Content CAS NO. Registered Holders
Cefaclor

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

More

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

53994-73-3 29
Sparfloxacin Tablets
5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Name Description Content CAS NO. Registered Holders
Sparfloxacin

This product is a quinolone antibacterial drug. It is a broad-spectrum antibacterial drug, which has obvious antibacterial effects on Gram-positive bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, and Enterococcus faecalis; it also has good antibacterial effects on Gram-negative bacteria Escherichia coli, Klebsiella, Salmonella, Shigella, Vibrio parahaemolyticus, Proteus, Enterobacter, Pseudomonas, Acinetobacter, Neisseria (Neisseria gonorrhoeae, etc.). This product also has good antibacterial effects on mycoplasma, chlamydia, Legionella, anaerobic bacteria including Bacteroides fragilis and Mycobacterium. The mechanism of action of this product is to inhibit the action of DNA gyrase in the process of bacterial DNA synthesis and play a bactericidal role.

More

This product is a quinolone antibacterial drug. It is a broad-spectrum antibacterial drug, which has obvious antibacterial effects on Gram-positive bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, and Enterococcus faecalis; it also has good antibacterial effects on Gram-negative bacteria Escherichia coli, Klebsiella, Salmonella, Shigella, Vibrio parahaemolyticus, Proteus, Enterobacter, Pseudomonas, Acinetobacter, Neisseria (Neisseria gonorrhoeae, etc.). This product also has good antibacterial effects on mycoplasma, chlamydia, Legionella, anaerobic bacteria including Bacteroides fragilis and Mycobacterium. The mechanism of action of this product is to inhibit the action of DNA gyrase in the process of bacterial DNA synthesis and play a bactericidal role.

110871-86-8 6
Sparfloxacin Tablets
The chemical component of this product is sparfloxacin. Its chemical name is 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid. Its molecular formula is C19H22F2N4O3. Its molecular weight is 392.41.
Name Description Content CAS NO. Registered Holders
Sparfloxacin

This product is a quinolone antibacterial drug, which has a good antibacterial effect on Gram-positive bacteria, Gram-negative bacteria, mycoplasma, chlamydia, Legionella, anaerobic bacteria and mycobacteria. Its mechanism of action is to inhibit DNA gyrase in the process of bacterial DNA synthesis to achieve bactericidal effect.

More

This product is a quinolone antibacterial drug, which has a good antibacterial effect on Gram-positive bacteria, Gram-negative bacteria, mycoplasma, chlamydia, Legionella, anaerobic bacteria and mycobacteria. Its mechanism of action is to inhibit DNA gyrase in the process of bacterial DNA synthesis to achieve bactericidal effect.

111542-93-9 0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.